Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Department of Urology, Keio University School of Medicine, Tokyo, Japan; Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan.
Urol Oncol. 2022 Feb;40(2):61.e1-61.e8. doi: 10.1016/j.urolonc.2021.07.005. Epub 2021 Jul 29.
We herein compared the diagnostic performance of Vesical Imaging-Reporting and Data System (VI-RADS) scoring with diagnostic cystoscopy and evaluated diagnostic accuracies based on tumor locations.
Among 112 bladder cancer patients who underwent multiparametric magnetic resonance imaging and diagnostic cystoscopy preoperatively to detect bladder cancer, 61 were analyzed. VI-RADS was categorized into 5 stages by 2 radiologists (R1 and R2). Cut-off values ≥3 indicated muscle-invasive bladder cancer (MIBC). Muscle invasion (MI) was visually evaluated using diagnostic cystoscopy by 2 urologists (U1 and U2). The sensitivity and specificity of VI-RADS scores and diagnostic cystoscopy for diagnosing MI were compared.
16 patients (26.2%) were pathologically diagnosed with MIBC. Regarding MI diagnostic accuracy, the sensitivity/specificity of VI-RADS scores were 93.8/88.9% by R1 and 87.5/86.7% by R2, while those of diagnostic cystoscopy were 56.3/68.9% by U1 and 68.8/84.4% by U2. Therefore, the diagnostic accuracy of VI-RADS was significantly higher than that of cystoscopy, particularly for tumors located on the bladder neck, trigone, dome, and posterior and anterior walls. Over- and under-diagnosis rates were higher with VI-RADS than with diagnostic cystoscopy (25.9% vs. 14.8%) for tumors located on the lateral wall or ureteral orifice.
VI-RADS had superior diagnostic performance for detecting MI, especially in tumors located at the bladder neck/trigone/dome/posterior and anterior wall. However, VI-RADS was inferior to cystoscopy in terms of MI detection for tumors located on the lateral wall or ureteral orifice. Therefore, a combination of diagnostic tools is recommended for the accurate staging of these tumors.
我们在此比较了 Vesical Imaging-Reporting and Data System (VI-RADS) 评分与诊断性膀胱镜检查的诊断性能,并根据肿瘤位置评估了诊断准确性。
在 112 例接受多参数磁共振成像和诊断性膀胱镜检查以检测膀胱癌的膀胱癌患者中,对 61 例进行了分析。由 2 名放射科医生(R1 和 R2)将 VI-RADS 分为 5 个阶段。如果评分≥3,则表示肌层浸润性膀胱癌(MIBC)。由 2 名泌尿科医生(U1 和 U2)使用诊断性膀胱镜检查来评估肌层浸润(MI)。比较了 VI-RADS 评分和诊断性膀胱镜检查对 MI 的诊断敏感性和特异性。
16 例(26.2%)患者病理诊断为 MIBC。关于 MI 诊断准确性,R1 的 VI-RADS 评分的敏感性/特异性为 93.8/88.9%,R2 的敏感性/特异性为 87.5/86.7%,而 U1 的诊断性膀胱镜检查的敏感性/特异性为 56.3/68.9%,U2 的敏感性/特异性为 68.8/84.4%。因此,VI-RADS 的诊断准确性明显高于膀胱镜检查,尤其是对于位于膀胱颈部、三角区、穹窿、前壁和后壁的肿瘤。对于位于侧壁或输尿管口的肿瘤,VI-RADS 的过度诊断和漏诊率高于诊断性膀胱镜检查(25.9%比 14.8%)。
VI-RADS 对 MI 的检测具有较高的诊断性能,特别是在位于膀胱颈部/三角区/穹窿/前壁和后壁的肿瘤中。然而,对于位于侧壁或输尿管口的肿瘤,VI-RADS 在 MI 检测方面逊于膀胱镜检查。因此,建议联合使用诊断工具以准确分期这些肿瘤。